230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by abrdn plc

abrdn plc purchased a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 230,745 shares of the company's stock, valued at approximately $1,719,000. abrdn plc owned 0.34% of EyePoint Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in shares of EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after buying an additional 4,172 shares during the period. Greenwich Wealth Management LLC grew its holdings in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after purchasing an additional 900 shares during the period. Cyndeo Wealth Partners LLC acquired a new position in EyePoint Pharmaceuticals during the third quarter valued at approximately $100,000. Intech Investment Management LLC acquired a new position in EyePoint Pharmaceuticals during the third quarter valued at approximately $136,000. Finally, GSA Capital Partners LLP grew its holdings in EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company's stock valued at $264,000 after purchasing an additional 18,616 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Up 3.0 %

Shares of EYPT stock traded up $0.19 during trading on Friday, reaching $6.50. The company's stock had a trading volume of 477,612 shares, compared to its average volume of 860,200. The business has a fifty day moving average price of $7.66 and a 200-day moving average price of $8.70. The company has a market cap of $443.63 million, a price-to-earnings ratio of -3.25 and a beta of 1.51. EyePoint Pharmaceuticals, Inc. has a one year low of $5.90 and a one year high of $29.95.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Chardan Capital restated a "buy" rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price target on the stock. Robert W. Baird cut their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday, November 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.